Novo Nordisk (NVO) Experiences Muted Sentiment From Analysts

We recently published 13 Best ADR Stocks to Invest In.  Novo Nordisk A/S (NYSE:NVO) is one of the best ADR stocks.

Healthcare giant Novo Nordisk A/S (NYSE:NVO)’s shares were downgraded by Argus Research to Hold from Buy on December 8th, The Fly reported. The firm’s GLP-1 drugs were at the heart of the downgrade, as the analyst report outlined that Novo Nordisk A/S (NYSE:NVO) was experiencing market share losses of the drugs and could end up facing competition from generic drugs. Additionally, Argus also pointed towards a weak drug pipeline as it remarked that Novo Nordisk A/S (NYSE:NVO)’s semaglutide trials for Alzheimer’s disease had failed to impress.

The research firm was referring to a November 24th data release by Novo Nordisk A/S (NYSE:NVO) that which saw the firm’s trial evaluating the potential of its semaglutide drug for Alzheimer’s disease fall short of market expectations. While the study had aimed to slow down mental decline in patients by 20%, Novo Nordisk A/S (NYSE:NVO) revealed that a drop in disease-related biomarkers did not lead to delayed disease progression.

The pharma company is also seeking to expand its weight loss drug markets, with a Reuters report suggesting Novo Nordisk A/S (NYSE:NVO) plans to expand to India. More recently, the firm received some relief in the country after a Delhi court blocked pharma firm Sun Pharma from selling a semaglutide formulation in India until Novo Nordisk A/S (NYSE:NVO)’s patent expires.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.